Zacks Investment Research on MSN10h
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio ...
Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025?
We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...